OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
RIPTACs: A groundbreaking approach to drug discovery
Zonghui Ma, Andrew A. Bolinger, Jia Zhou
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103774-103774
Open Access | Times Cited: 9
Zonghui Ma, Andrew A. Bolinger, Jia Zhou
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103774-103774
Open Access | Times Cited: 9
Showing 9 citing articles:
Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics
Qichao Bao, Anil Kumar, Daqing Wu, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 6, pp. 103986-103986
Open Access | Times Cited: 6
Qichao Bao, Anil Kumar, Daqing Wu, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 6, pp. 103986-103986
Open Access | Times Cited: 6
An updated patent review of BRD4 degraders
Zonghui Ma, Cun Zhang, Andrew A. Bolinger, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 929-951
Closed Access | Times Cited: 6
Zonghui Ma, Cun Zhang, Andrew A. Bolinger, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 929-951
Closed Access | Times Cited: 6
A review of the patent literature surrounding TRPV1 modulators
Isabel Devesa, Gregorio Fernández‐Ballester, Asia Fernández‐Carvajal, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Isabel Devesa, Gregorio Fernández‐Ballester, Asia Fernández‐Carvajal, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains
Chuhui Huang, Claire L. Harris, Ghizal Siddiqui, et al.
ACS Pharmacology & Translational Science (2025)
Closed Access
Chuhui Huang, Claire L. Harris, Ghizal Siddiqui, et al.
ACS Pharmacology & Translational Science (2025)
Closed Access
Deubiquitinase-Targeting Chimeras (DUBTACs) as a Potential Paradigm-Shifting Drug Discovery Approach
Zonghui Ma, Mingxiang Zhou, Haiying Chen, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Zonghui Ma, Mingxiang Zhou, Haiying Chen, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Protein degraders - from thalidomide to new PROTACs
Takumi Ito
The Journal of Biochemistry (2023) Vol. 175, Iss. 5, pp. 507-519
Open Access | Times Cited: 10
Takumi Ito
The Journal of Biochemistry (2023) Vol. 175, Iss. 5, pp. 507-519
Open Access | Times Cited: 10
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery
Andrew A. Bolinger, Jun Li, Xuping Xie, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1023-1041
Closed Access | Times Cited: 1
Andrew A. Bolinger, Jun Li, Xuping Xie, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1023-1041
Closed Access | Times Cited: 1
BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease
Zonghui Ma, Andrew A. Bolinger, Irina V. Pinchuk, et al.
Advances in pharmacology (2024), pp. 203-236
Closed Access | Times Cited: 1
Zonghui Ma, Andrew A. Bolinger, Irina V. Pinchuk, et al.
Advances in pharmacology (2024), pp. 203-236
Closed Access | Times Cited: 1
Recent Advances in Developing Targeted Protein Degraders
Binbin Cheng, Hongqiao Li, Xiaopeng Peng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117212-117212
Closed Access
Binbin Cheng, Hongqiao Li, Xiaopeng Peng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117212-117212
Closed Access
